Aurora Cannabis Inc. Common Shares (ACB)
ACB trades on Nasdaq in Health Care, Medicinal Chemicals and Botanical Products . Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC filing XBRL, 40-F (ifrs-full:RevenueFromContractsWithCustomers), fiscal year ended 2026-03-31, https://www.sec.gov/Archives/edgar/data/1683541/000162828026042364/0001628280-26-042364-index.htm. Net income: SEC 40-F (ifrs-full:ProfitLoss), fiscal year ended 2026-03-31. Converted from CAD at 1.4258 per USD (today's ECB or Federal Reserve reference rate).
Profile
| Field | Value |
|---|---|
| Ticker | ACB on Nasdaq |
| Sector | Health Care |
| Industry | Medicinal Chemicals and Botanical Products |
| Country | Canada |
| IPO year | Not reported by the screener |
| SEC CIK | 0001683541 |
| Canadian listing | TSX: ACB |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $224.9M |
| Net income | -$95.4M |
| Operating income | Not in SEC XBRL data |
| Net margin | -42.4% |
| Operating margin | Operating income not reported |
| Revenue growth | -6.6% |
| Cash | $45.4M |
| Total assets | $421.6M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 1.3× |
Reported in CAD; shown in US dollars.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 40-F 2026-06-11 |
| Cash and burn | 64.7M CAD cash; operating cash flow -3.4M CAD a quarter. | Report 2026-03-31 |
| Shares outstanding | 58,947,593 (2026-03-31); 56,234,231 a year earlier; 345,269,310 three years earlier. 3y figure adjusted for splits (1-for-10 overall); the newest SEC cover-page count is from 2026-03-31; shares issued since then are not in these figures. | Cover page 2026-03-31 |
| Reverse splits, 3 years | 1; latest 1-for-10 on 2024-02-20 | Source 2024-02-20 |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, Vancouver, Canada | PCAOB Form AP 2026-07-03 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2026 2026-03-31 | 320.6M CAD | -136.0M CAD | -13.5M CAD | 64.7M CAD | 0 CAD | 320.6M CAD | 40-F 2026-06-11 |
| FY 2025 2025-03-31 | 343.3M CAD | 1.6M CAD | 16.0M CAD | 137.9M CAD | 42.5M CAD | 343.3M CAD | 40-F 2025-06-18 |
| FY 2024 2024-03-31 | 269.6M CAD | -69.3M CAD | -68.5M CAD | 136.1M CAD | 38.2M CAD | 269.6M CAD | 40-F 2025-06-18 |
| FY 2022 2022-06-30 | 221.3M CAD | -1.7B CAD | -110.3M CAD | 437.8M CAD | 0 CAD | 221.3M CAD | 40-F 2023-06-14 |
| FY 2021 2021-06-30 | 245.3M CAD | -692.0M CAD | -210.6M CAD | 421.5M CAD | 0 CAD | 245.3M CAD | 40-F 2022-09-21 |
| FY 2020 2020-06-30 | 268.7M CAD | -3.3B CAD | -342.1M CAD | 162.2M CAD | 204.2M CAD | 268.7M CAD | 40-F 2021-09-27 |
| FY 2019 2019-06-30 | 245.5M CAD | -293.5M CAD | -192.2M CAD | 172.7M CAD | 141.2M CAD | 245.5M CAD | 40-F 2020-09-25 |
| FY 2018 2018-06-30 | 55.2M CAD | 71.9M CAD | -81.7M CAD | 76.8M CAD | 11.7M CAD | 55.2M CAD | 40-F 2019-09-11 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months). Amounts in CAD.
Key SEC documents
The SEC filing list did not load in time for this page. It is on SEC EDGAR and in the full dossier.
Price moves
| Window | Return |
|---|---|
| 1 week | -5.7% |
| 1 month | +15.2% |
| 3 months | +30.3% |
| Year to date | +17.1% |
| 1 year | +12.5% |
| From 52-week high | -11.3% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Medicinal Chemicals and Botanical Products
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| SNDL | SNDL Inc. Common Shares | $1.34 | -2.19% | $326.0M |
| TLRY | Tilray Brands Inc. Common Stock | $2.34 | -3.70% | $345.8M |
| USNA | USANA Health Sciences Inc. | $13.54 | +2.27% | $250.3M |
| CGC | Canopy Growth Corporation Common Shares | $0.5460 | -2.71% | $231.2M |
| MDWD | MediWound Ltd. | $13.55 | +5.04% | $195.0M |
| OBIO | Orchestra BioMed Holdings Inc. | $7.12 | -1.79% | $560.4M |
| NAGE | Niagen Bioscience Inc. | $2.01 | -2.66% | $159.2M |
| GLAS | Glass House Brands Inc. Subordinate Voting Shares | $1.29 | +1.57% | $113.5M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier